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Background: Tumor-induced osteomalacia (TIO) is a rare disorder, which is commonly found in craniofacial locations
and in the extremities. To the best of our knowledge, only 16 cases have been described in the spine, and this is the
first report to describe a case of patient with TIO in the thoracic spine combined with a mesenchymal hamartoma
which had confused the therapeutic strategies to date.
Case description: We report the case of a 60-year-old patient with hypophosphatemia and presented with limb
weakness. Treating with phosphate did not correct the hypophosphatemia and an 111In pentetreotide scintigraphy
(octreotide scan) revealed an increased uptake at the right forearm. The tumor was resected totally, and the
histopathology revealed a mesenchymal hamartoma, but we noticed that hypophosphatemia was not corrected
after the tumor resection. Then a whole-body magnetic resonance imaging (WB-MRI) was performed and the
results revealed tumorous tissues at the right T1 vertebral pedicle. The tumor was removed with an en bloc
method, and the pathology showed phosphaturic mesenchymal tumor. Follow-up at 1 year after surgery revealed no
recurrence, and the serum phosphorus level of the patient was normal.
Conclusions: Tumor-induced osteomalacia is exceedingly rare with only 16 cases in spine published in the literature. It
is difficult to find and leads to years of suffering debilitating complications. In this regard, the WB-MRI is a better
method to locate the real tumor. Treating with phosphate can only relieve symptoms, and a complete surgical
removal remains the gold standard treatment.
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Tumor-induced osteomalacia (TIO), also known as onco-
genic osteomalacia, is a rare paraneoplastic syndrome,
which is characterized by hyperphosphaturia, hypopho-
sphatemia, and increased levels of alkaline phosphatase
[1,2]. Clinical characteristics often include bone pain,
pathologic fractures, and musculoskeletal weakness [3],
which are related to renal phosphate wasting and resultant
reduction in bone mineralization [2,4,5]. TIO was first
described in 1947 by McCance and colleagues [6] who
reported a 15-year-old girl exhibiting osteomalacia with* Correspondence: songdw@sh163.net; jianruxiao83@163.com
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unless otherwise stated.vitamin D resistance. Unfortunately, he did not attribute
her osteomalacia to femoral tumor.
In this report, we illustrate the clinical presentation
and therapeutic strategy of a patient with a TIO in
thoracic spine. He underwent an en bloc resection to at-
tain oncological and metabolic control. To date, about
300 cases have been described in the world’s literature
[7], and only 16 cases were located in the spine [5,8-19].
To our best knowledge, it is the first report to describe a
mesenchymal hamartoma which confused the real loca-
tion of TIO. In this report, we also comprehensively
reviewed those cases of TIO in spine published in the
English language literature, paying particular attention
to the clinical presentation and therapeutic strategy of
the reported tumors.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Preoperative gadolinium-enhanced T1-weighted magnetic
resonance image (MRI). Axial image shows osteolytic lesion with a
relatively smooth margin in the T1 right vertebral pedicle and
heterogeneously enhanced with gadolinium.
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The patient, a 60-year-old man, first noticed pain in his
right foot in 2007. In 2008, he came to the primary hos-
pital presenting with low back pain, gait disturbance, and
muscle weakness in the right lower limb. Radiological
examination did not reveal any pathologic change in the
lumbar vertebrae, whereas a bone scan revealed markedly
increased bone uptake at the whole skeleton, and positron
emission tomography/computed tomography (PET/CT)
revealed mild increased uptake at multiple ribs and right
femoral trochanter. No regular treatment was performed.
Then the patient’s symptoms were progressively worsened
and he became disabled. In 2010, blood examination re-
vealed hypophosphatemia (0.5 mg/dl; normal range 0.98
to 1.62 mg/dl), hypocalcemia (2.17 mmol/L; normal range
2.25 to 2.75 mmol/L), reduced 1,25-dihydroxy vitamin D
(10.5 pg/ml; normal range 11.1 to 42.9 pg/ml), and ele-
vated β-C-terminal telopeptide of type I collagen (CTX)
(1426 pg/L; normal range 100 to 650 pg/L). Osteomalacia
was initially diagnosed and treated with phosphate, cal-
cium, vitamin D, and calcitriol. Although blood exam-
ination still revealed hypophosphatemia (0.55 mg/dl),
symptoms got better progressively. In 2012, an 111In
pentetreotide scintigraphy (octreotide scan) was performed,
and the result revealed a markedly increased uptake at the
right forearm. The tumor was resected totally, and the
histopathology revealed a mesenchymal hamartoma, but
we noticed that hypophosphatemia wasn’t corrected after
the tumor resection. In 2013, the patient suffered paraple-
gia and then a PET/CT scan was performed. Unfortu-
nately, PET/CT scan did not locate the tumor, and thus,
he underwent to a whole-body magnetic resonance im-
aging (WB-MRI), which revealed tumorous tissues at
the right T1 vertebral pedicle.
The 60-year-old man was presented to our spine tumor
center for consultation regarding resection of the tumor
in the right T1 vertebral pedicle. On presentation to our
center, the patient had signs of severe osteomalacia, and
the patient’s most outstanding complaints were diffuse
bone pain throughout the whole skeleton, limb weakness,
hypaesthesia, and disabled walking. Physical examination
revealed that motor strength was graded as 3/5 in the
upper limbs and 1/5 in the lower limbs. Sensation de-
creased slightly throughout, with hyporeflexia. The
Hoffmann sign and the Babinski sign were negative.
Blood tests revealed hypophosphatemia (0.51 mg/dl),
hypocalcemia (2.15 mmol/L), elevated levels of parathy-
roid hormone (PTH) (72.3 pg/mL; normal range 12 to
65 pg/mL), normal serum alkaline phosphatase (ALP)
levels (313 U/L; normal range 115 to 359 U/L), and normal
levels of 1,25-dihydroxy vitamin D (21.01 pg/ml).
Radiological exams demonstrated osteolytic changes
of the T1 right vertebral pedicle and mild collapse of
the T1 vertebral body. In addition, some fractures weredetected in multiple ribs. MRI revealed a tumor in the
T1 vertebral body and right vertebral pedicle (Figure 1).
The tumor showed iso-signal intensity on a T1-weighted
image (T1WI), high-signal intensity on T2WI, and was
heterogeneously enhanced by gadolinium.
Surgery
Written informed consent was obtained. We decided to
remove the whole metabolically active tissue via an en
bloc method, and bilateral vertebral pedicles were used
to accomplish spinal reconstruction. Care was taken to
resect the tumor around its margins, and cuts were made
in the bone outside of the tumor margin to minimize spill-
age of tumor. A titanium mesh cage was placed in the
position of the T1 vertebral body and was packed with re-
combinant human BMP-2 matrix. A gross total resection
was performed without intraoperative complications, and
the specimen was sent for pathologic diagnosis (Figure 2).
Histopathology
The cells appeared spindled with normochromatic, small
nuclei, and indistinct nucleoli. No significant nuclear
atypia and mitoses were found. The tumor cells were
focally embedded in a myxochondroid and osteoid-like
matrix and contained cystic spaces of many sizes, including
Figure 2 Tumor specimen.
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tumor was well-vascularized, and bone invasion was fo-
cally present (Figure 3b). Immunohistochemical staining
was positive for CD34 (Figure 3c), Vimentin, and S100,
with a quite low proliferation index (Ki-67 1% to 3%).
Phosphaturic mesenchymal tumor (PMT) was diagnosed
in the patient.
Follow-up
After surgery, the patient stayed in bed for 1 month, and
1.5 μg/day of calcitriol was orally administered. The
clumsiness and muscle weakness in both legs of the pa-
tient gradually improved, with motor strength graded asFigure 3 Histopathology of the tumor. (a) The tumor mainly comprises sh
(Hematoxylin and eosin [H & E]); (b) Some areas of vascular proliferation
Immunostaining for CD34 reveals many tumor cells with positive staining4/5 in the lower limbs at the 6 months follow-up and
the grade remained at this level thereafter (Figure 4a).
When he walked, he wore a cervicothoracic brace. The
patient experienced no multiple bone pain or new neuro-
logic deficits during the 1-year follow-up period. One year
after the surgery, the patient had normal neurologic func-
tion, normal triceps, biceps knee, and ankle jerks, and he
returned to work. Serum phosphorus levels slightly fluctu-
ated, but the levels remained within the normal range
(Figure 4b). Bone union without loss of cervicothoracic
physiological curvature was confirmed by radiological
examination at the 1-year follow-up. No evidence of re-
current tumor was detected in the MRI. The patient hadort spindle cells with deeply stained nuclei. Few mitoses are observed
show larger vessels arranged in a ‘staghorn’ pericytoma pattern; (c)
in the cytoplasm.
Figure 4 Follow-up. (a) Change of motor strength Change; (b) Change
of serum phosphorus level.
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tected. In addition, we confirmed the accurate bony union
of the fractured ribs.
Discussion
Osteomalacia is a metabolic bone disorder characterized
by impaired mineralization of osteoid matrix in mature
bone. It is most commonly caused by rare inborn disor-
ders of metabolism, such as inherited hypophosphatemic
rickets and X-linked hypophosphatemia (XLH), or may be
associated with more common processes such as renal
failure [11]. TIO is the most unusual type of osteomalacia,
which is commonly found in craniofacial locations and in
the extremities [1], along with long-standing hypopho-
sphatemia [1,20,21]. This article presents an unusual case
of phosphaturic mesenchymal tumor in the thoracic spine.
To our best knowledge, including this one, only 16 TIOshave been described in the English literature in spine
(Table 1).
TIO can lead to debilitating complications and years
of suffering. The average age of 16 cases is 48.0 (range
14 to 72) years. It occurs in any age, with preponderance
around the fifth decades. Characteristically, TIO affects
adults without a predilection for gender, with nine fe-
male and seven male in all the spinal TIOs. Diffuse bone
pain, caused by poor bone mineralization, is the most
frequent symptom in these patients [1]. If treated inad-
equately, severe osteomalacia may lead to progressive
myalgias in adults and gait disturbances, growth stunt-
ing, and skeletal deformities in children [18].
Notably, one of the most challenging aspects of TIO is
to find the tumor. The occult nature of TIO delays its
recognition, and in our case, we employed 6 years to
identify the real tumor which may attribute to the mes-
enchymal hamartoma in the same patient complicating
the final diagnosis. In a literature review of all the TIOs
[7], the average time from onset of symptoms to a con-
firmed diagnosis often exceeds 2.5 years. Definitive treat-
ment is further delayed by an average of 5 years due to
inability to find the underlying tumor due to the charac-
teristics of being small and slow growing and being lo-
cated in peculiar or atypical sites.
Typical laboratory findings include hyperphosphaturia,
elevated ALP, and low serum levels of vitamin D3, which
account for 14/15, 10/15, and 5/15 in the literature, re-
spectively [1,22]. Hypophosphatemia is secondary to inhib-
ition of renal phosphorus reabsorption, and the vitamin D
synthetic defect blocks the compensatory rise of calcitriol
stimulated by the hypophosphatemia [22]. Moreover, fibro-
blast growth factor-23 (FGF-23), associated with iron
in a pathophysiological mechanism of TIO [23,24], is
highly expressed in TIO tumors compared with normal
tissues [1,20,21].
Radiographically, it presents with bone cortical thick-
ness, osteoporosis, and fracture [25]. Unfortunately, TIO
tumors could not be detected by conventional imaging
techniques in all 16 cases. The classic detecting method of
TIO is 111In pentetreotide scintigraphy (octreotide scan), a
scanning technique that detects the expression of somato-
statin receptors (SSTRs) [26,27]. However, a nonspecific
uptake may cause a false-positive scan due to inflamma-
tory tissues, fractures, or other tumor, as lymphocytes can
express octreotide receptors, and moreover, a negative
octreotide scan cannot exclude a diagnosis of TIO. False-
positive scan emphasizes the need to further identify the
tumor by PET/CT or WB-MRI exams. Successful tumor
localization has also been reported in some patients with
PET/CT [28,29]. However, considering the small and oc-
cult nature of TIO, it might not be seen as increased up-
take of PET/CT utilization [30]. WB-MRI has been well
established to have no radiological exposure and offers
Table 1 Characteristics of spinal cases of TIO




symptoms Preoperative lab Treatment Histological
diagnosis
Outcomes
1 Boriani et al,
1978 [8]
S1-3 18, M DNMI Bone pain, weakness Hypophosphatemia, elevated ALP Complete resection,
radiotherapy
Osteosarcoma NOLF
2 Stone et al,
1992 [9]
T3-4 33, F DNMI Bone pain, weakness,
fractures
Hypophosphatemia Complete resection,
supplementation of vitamin D,
phosphate, and calcium
Neuroendocrine tumor NOLF
3 Yu et al,
1995 [10]





supplementation of vitamin D
and phosphate
PMT PSA
4 Terek et al,
2001 [11]
S1-2 14, M 1+ Bone pain, skeletal
abnormalities
Hypophosphatemia, hypocalcemia,




5 Dissanayake et al,
2003 [37]
L2 58, M 3+ Musculoskeletal pains,
fractures
Hypophosphatemia, low level of
vit D3, elevated ALP
Complete resection Haemangiopericytoma NOLF
6 Folpe et al,
2004 [5]
C1 32, F 4 DNMI DNMI Partial resection, radiotherapy Malignant PMTMCT PSA recurrence
7 Chua et al,
2008 [12]
T3 34, F 1 Musculoskeletal pain,
fatigue
Hypophosphatemia, hypocalcemia,
elevated ALP and PTH
Partial resection, supplementation
of phosphate and calcitriol
Plasmacytoma DNMI
8 Sciubba et al,
2009 [13]
T8 56, F 5 Bone pain, weakness,
fractures
Hypophosphatemia, low level of
vitamin D3, elevated ALP and PTH
Complete resection PMT NOLF
9 Pirola et al,
2009 [14]
T4 57, M DNMI Fractures, paresthesias Hypophosphatemia, low level of
vitamin D3, elevated ALP and PTH
Complete resection,
supplementation of vitamin D
and phosphate
PMT NOLF
10 Mavrogenis et al,
2010 [15]
S1 42, F 2 Bone pain,
paresthesias
Normal Complete resection PMTMCT NOLF
11 Marshall et al,
2010 [16]
T12 55, F 6+ Bone pain; fractures Hypophosphatemia Complete resection PMTMCT DNMI
12 Akhter et al,
2011 [17]
C5 52, M 1 Fracture Hypophosphatemia Complete resection,
supplementation of vitamin D,
and phosphate
PMTMCT NOLF
13 Gandhi et al,
2012 [18]
L4 66, F 2, Bone pain, weakness Hypophosphatemia, hypocalcemia,
low level of vit D3, elevated ALP
and PTH
Complete resection PMTMCT NOLF
14 Nakamura et al,
2014 [19]






15 Puthenveetil et al
[38]
T12 61, F 7 Musculoskeletal pain,
weakness, fractures
Hypophosphatemia, increased ALP Complete resection,
supplementation of calcium and
phosphate
PMTMCT NOLF







PMTMCT: phosphaturic mesenchymal tumor mixed connective tissue type; PMT: phosphaturic mesenchymal tumor; DNMI: Did not mention it; PSA: persistent serum abnormalities; ALP: alkaline phosphatase; NOLF:
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subcutaneous regions. Moreover, majority of TIOs
which had been reported to be located in the bone, soft
tissue, and subcutaneous region have a small size. Ac-
cordingly, WB-MRI is advantageous for detecting such
kinds of tumor [31,32].
The ideal treatment for TIO is complete tumor resec-
tion, and this corrects the biochemical abnormalities and
remineralizes the bone substance in most cases (12/16)
[33]. The partial resection (4/16) might also lead to per-
sistent serum abnormalities remained or even tumor
recurrence (#6). It is worth noting that osteomalacia
may reduce bone resistance and increase the risk of
nonunion or lead to delayed union [34]. Therefore, rigid
internal fixation and effective brace should be insured
[35,36]. With regard to TIO without accurate location, the
combination of vitamin D, phosphorus supplementation,
and calcitriol can be used to replace progressive renal
phosphorus loss, promote renal production of 1,25-
dihydroxy vitamin D, and enhance renal phosphorus
reabsorption. However, medical therapy cannot main-
tain long-term efficacy and potential complications should
also be watched out, such as hyperparathyroidism, hyper-
calcemia, and kidney stone formation [1].
Conclusion
Tumor-induced osteomalacia is exceedingly rare with only
16 cases in spine published in the literature. It is difficult
to find and leads to years of suffering debilitating compli-
cations. In this regard, WB-MRI is one of the important
options to detect the real tumor. Treating with phosphate
can only relieve symptoms, and completing surgical re-
moval remains the modality of choice.
Consent
Written informed consent was obtained from each patient
for publication of this study and the accompanying
images.
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